Aromatase inhibitors (AIs) are the current endocrine therapy of choice for postmenopausal women diagnosed with hormone receptor (HR)-positive breast cancer, given their superior efficacy over tamoxifen in lowering cancer recurrence. The gene discussed is CYP19A1; the disease is breast cancer.